| Savolitinib studied in …STUDIED_INderived34 of 34show fewer |
|---|
| → studied in | NCT05009836Phase 3 · active not recruiting Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC · 34 trials list this drug (13 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05374603Phase 2 · active not recruiting Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC · 34 trials list this drug (13 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05261399Phase 3 · active not recruiting Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment · 34 trials list this drug (13 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03598244Phase 1 · active not recruiting Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors · 34 trials list this drug (13 active) | — | — | Medulloblastoma,Primary Central Nervous System Neoplasm,Malignant Glioma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03091192Phase 3 · active not recruiting Savolitinib vs. Sunitinib in MET-driven PRCC. · 34 trials list this drug (13 active) | — | — | Neoplasm by Site,Carcinoma,Urinary Tract Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05043090Phase 3 · active not recruiting Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC · 34 trials list this drug (13 active) | — | — | Papillary Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04923932Phase 2 · completed Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients · 34 trials list this drug (13 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03778229Phase 2 · active not recruiting Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib · 34 trials list this drug (13 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06563999Phase 2 · recruiting Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. · 34 trials list this drug (13 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05620628Phase 2 · recruiting Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2) · 34 trials list this drug (13 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03385655Phase 2 · active not recruiting Prostate Cancer Biomarker Enrichment and Treatment Selection · 34 trials list this drug (13 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04923945Phase 3 · completed Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients · 34 trials list this drug (13 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03944772Phase 2 · active not recruiting Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) · 34 trials list this drug (13 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02761057Phase 2 · completed Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed · 34 trials list this drug (13 active) | — | — | Papillary Renal Cell Carcinoma,Renal Cell Carcinoma,Type 1 Papillary Renal Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06692491Phase 2 · not yet recruiting Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · 34 trials list this drug (13 active) | — | — | Rare Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02819596Phase 2 · completed MEDI4736 Combinations in Metastatic Renal Cell Carcinoma · 34 trials list this drug (13 active) | — | — | Clear Cell Renal Cell Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03833440Phase 2 · unknown Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance · 34 trials list this drug (13 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05163249Phase 2 · unknown Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC · 34 trials list this drug (13 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02117167Phase 2 · completed SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients · 34 trials list this drug (13 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03592641Phase 2 · terminated Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer · 34 trials list this drug (13 active) | — | — | Colorectal Carcinoma,Colon Adenocarcinoma,Malignant Colon Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05777278Phase 1/Phase 2 · recruiting Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression · 34 trials list this drug (13 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02447406Phase 1/Phase 2 · completed Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment · 34 trials list this drug (13 active) | — | — | Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02897479Phase 2 · unknown A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer · 34 trials list this drug (13 active) | — | — | Lung Sarcomatoid Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04187456Phase 1 · completed A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body · 34 trials list this drug (13 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02127710Phase 2 · completed A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) · 34 trials list this drug (13 active) | — | — | Papillary Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04675021Phase 1 · completed Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects · 34 trials list this drug (13 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04179071Phase 1 · completed A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine · 34 trials list this drug (13 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02374645Phase 1 · completed A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC · 34 trials list this drug (13 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04118842Phase 1 · completed A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin · 34 trials list this drug (13 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03258515Phase 1 · completed A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers · 34 trials list this drug (13 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04121910Phase 1 · completed A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole · 34 trials list this drug (13 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01985555Phase 1 · completed Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors · 34 trials list this drug (13 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01773018Phase 1 · completed Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors · 34 trials list this drug (13 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02252913Phase 1 · completed A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer · 34 trials list this drug (13 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |